AEterna Zentaris (AEZS) Announces Phase 2 Results of AEZS-108 Endometrial Cancer Treatment
Tweet Send to a Friend
AEterna Zentaris Inc. (NASDAQ: AEZS) today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
